Dolutegravir (Tivicay)
The Latest
Dovato for HIV Treatment: Everything You Need to Know
What makes this two-drug regimen for HIV so unique? An expert HIV clinician walks us through the details.
Immediate HIV Treatment Initiation With Integrase Inhibitors Leads to Large Drop in Secondary HIV Transmission Among MSM
Integrase inhibitors are known to be potent first-line therapy options. Recent research suggests their benefits extend to onward HIV prevention as well.
Researcher Behind "Brazil Patient," the Latest HIV Remission Case, Explains How It Happened
The international news story that broke at AIDS 2020, explained by the lead researcher.
HIV Clinical Research Highlights From AIDS 2020, the 23rd International AIDS Conference
COVID-19 or no, there was still plenty to learn at this year's virtual conference, including for U.S. clinicians seeking to improve the care and treatment they provide to their patients living with HIV.
Tempering Previous Concerns, Study Finds Dolutegravir Safest HIV Treatment During Pregnancy
New data shows the drug is not more likely to cause birth defects.
This Week in HIV Research: Playing Catchup on the Aging Front
March 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions.
This Week in HIV Research: Do You Believe in U=U?
Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.
This Week in HIV Research: Bone Concerns Aren’t Just for Older Folks
Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.
Tsepamo Study Provides Critical Update on Neural Tube Defects and Dolutegravir
A lot of pregnancies in Botswana were anxiously followed after results from the Tsepamo study were revealed in late 2018. Updated data provide a medium-sized sigh of relief.
DAWNING Study Casts New Light on the Details of Resistance
The findings will help providers manage patients who have known or potential resistance to NRTIs, but who we want to place on a simplified antiretroviral regimen.